China Severe Combined Immunodeficiency (SCID) Market (2026-2032) | Challenges, Companies, Pricing, Size, Strategy, Restraints, Demand, Revenue, Investment Opportunities, Competition, Growth, Forecast, Analysis, Drivers, Trends, Outlook, Share, Insights, segmentation, Value

Market Forecast By Treatment Type (Gene Therapy, Bone Marrow Transplant, Enzyme Replacement, Antimicrobial Therapy), By Therapy Approach (Targeted DNA Editing, Donor Stem Cells, PEG-ADA Therapy, Infection Prevention), By Delivery Mode (IV or Injection, Inpatient Procedure, Regular Infusion, Oral/IV), By End User (Pediatric Hospitals, Specialty Clinics, Genetic Disorder Centers, Immunology Specialists) And Competitive Landscape
Product Code: ETC15465904 Publication Date: Oct 2026 Product Type: Market Research Report
Publisher: 6Wresearch Author: Dhaval Chaurasia No. of Pages: 110 No. of Figures: 55 No. of Tables: 12
Market Size, 2025 USD 459.0 million
Market Size, 2032 USD 641.57 million
CAGR, 2026–2032 4.9%

China Severe Combined Immunodeficiency (SCID) Market Size & Growth Rate

China Severe Combined Immunodeficiency (SCID) Market Size & Growth Rate

According to 6Wresearch internal database and industry insights, the China Severe Combined Immunodeficiency (SCID) Market was valued at USD 459.0 million in 2025 and is projected to reach USD 641.57 million by 2032, growing at a CAGR of approximately 4.9% during 2026–2032.

China Severe Combined Immunodeficiency (SCID) Market Highlights

Report Metric Details
Report Name China Severe Combined Immunodeficiency (SCID) Market
Market Size 2025 USD 459.0 million
Market Size 2032 USD 641.57 million
Absolute Growth 2025–2032 USD 182.57 million
CAGR 2026–2032 4.9%
Peak Annual Growth 6.9% in 2030
Forecast Period 2026–2032
Historical Data 2022–2025
Base Year 2025
Leading Treatment Type, 2025 Gene Therapy (42% share)
Leading Therapy Approach, 2025 Targeted DNA Editing (43% share)
Leading Delivery Mode, 2025 IV or Injection (42% share)
Leading End User, 2025 Pediatric Hospitals (49% share)
Fastest-Growing Therapy Approach Donor Stem Cells (7.1% CAGR)
Fastest-Growing Delivery Mode Regular Infusion (6.7% CAGR)
Fastest-Growing End User Genetic Disorder Centers (6.3% CAGR)
Growing Sector Pediatric Care
Key End Users Pediatric Hospitals, Genetic Disorder Centers, Specialty Clinics, Immunology Specialists

China Severe Combined Immunodeficiency (SCID) Market Year-wise Growth Rate and Key Drivers (2022–2032)

This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.

China Severe Combined Immunodeficiency (SCID) Market Year-wise Growth Rate and Key Drivers (2022–2032)

Annual growth estimates for each year appear below with the principal reason behind them, explaining the shifts that set the pace of the market.

Year Estimated Annual Growth (%) Market Rationale
2022 3.9 The market showed steady growth due to increased awareness of SCID treatments.
2023 3.4 Growth slowed slightly as healthcare facilities adjusted to new treatment protocols.
2024 4.2 Demand increased as more pediatric hospitals reported SCID cases.
2025 6.1 Growth accelerated with the rising adoption of gene therapy in treatment plans.
2026 6.4 The market continued to grow as gene therapy gained traction among healthcare providers.
2027 5.7 Growth slowed due to challenges in treatment accessibility for patients.
2028 2.3 A further slowdown occurred as the market adjusted to evolving treatment guidelines.
2029 3.3 Demand increased again as infection prevention strategies were reinforced in pediatric care.
2030 6.9 Growth peaked with the introduction of new gene therapy products for SCID.
2031 3.7 The market experienced a slowdown as healthcare providers adapted to new therapies.
2032 6.1 Growth resumed as genetic disorder centers expanded their treatment capabilities.

Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.

China Severe Combined Immunodeficiency (SCID) Market Synopsis

Severe Combined Immunodeficiency (SCID) Market in China encompasses treatments for a rare genetic disorder affecting immune system development. Treatments include gene therapy, bone marrow transplants, and enzyme replacement therapies. The market is growing due to increasing support from the National Health Commission for genetic disorder research and treatment. In 2023, over 200 pediatric hospitals reported SCID cases, highlighting the rising demand for effective therapies. Ongoing advancements in genetic therapies and supportive care are driving further growth in this sector.

Market Dynamics Impact Analysis (2026–2032)

Factor Type Impact Primary Segment Affected
Support from the National Health Commission for genetic disorder research Driver High Gene Therapy
Growing number of pediatric hospitals reporting SCID cases Driver High Bone Marrow Transplant
Expansion of genetic disorder centers across the country Opportunity High Genetic Disorder Centers
Increased funding for rare disease research Opportunity High Pediatric Hospitals
Limited access to advanced therapies in rural areas Restraint High Gene Therapy
High costs associated with gene therapy treatments Restraint High Bone Marrow Transplant
Delays in regulatory approvals for new therapies Challenge Medium Gene Therapy
Shortage of trained healthcare professionals for SCID treatment Challenge Medium Pediatric Hospitals

Evaluation of Drivers in China Severe Combined Immunodeficiency (SCID) Market (2026–2032)

The table below links each growth driver to the segment it affects and the evidence for it.

Drivers Primary Segment Affected Why It Matters (Evidence)
Support from the National Health Commission for genetic disorder research Gene Therapy This support has led to increased funding of 500 million CNY for SCID treatments, improving access for patients.
Growing number of pediatric hospitals reporting SCID cases Bone Marrow Transplant As awareness of SCID increases, more hospitals are equipped to provide necessary treatments, driving demand.
Expansion of genetic disorder centers across the country Genetic Disorder Centers The establishment of over 50 centers facilitates better diagnosis and treatment options for SCID patients.
Increased funding for rare disease research Pediatric Hospitals In 2022, the government allocated 500 million CNY for research, improving treatment access for SCID patients.
Introduction of new gene therapy products Gene Therapy The approval of new therapies streamlines access and encourages more hospitals to adopt these treatments.

Expansion of the Severe Combined Immunodeficiency (SCID) market in China is backed by increased funding for rare disease research, growing awareness among healthcare providers, and the establishment of specialised genetic disorder centres. The number of pediatric hospitals reporting SCID cases exceeded 200 in 2023, driving demand for effective therapies. The introduction of new gene therapy products has streamlined access for patients, encouraging healthcare providers to adopt advanced treatments. This combination of factors is increasing the market's growth potential.

Evaluation of Restraints in China Severe Combined Immunodeficiency (SCID) Market

The key brakes on demand, and where they bite hardest, are shown below.

Market Restraint Primary Segment Affected Why It Matters (Evidence)
Limited access to advanced therapies in rural areas Gene Therapy Patients in remote regions often face challenges accessing specialized SCID treatments, delaying care.
High costs associated with gene therapy treatments Bone Marrow Transplant The expensive nature of gene therapies can deter families from pursuing necessary treatments for SCID.
Delays in regulatory approvals for new therapies Gene Therapy Long approval processes can slow the introduction of new treatments, impacting patient access.
Shortage of trained healthcare professionals for SCID treatment Pediatric Hospitals A lack of specialists can limit the availability of effective care for SCID patients.
Inconsistent infection prevention strategies across facilities Infection Prevention Variability in protocols can lead to increased risk of infections in vulnerable SCID patients.

China Severe Combined Immunodeficiency (SCID) Market Challenges

Severe Combined Immunodeficiency treatment in China faces a skills shortage, as specialised training in genetic disorders is lacking. This gap delays diagnosis and treatment for SCID patients, impacting over 200 hospitals that reported cases in 2023. High treatment costs remain a barrier; gene therapy and bone marrow transplants can exceed 1 million CNY, limiting access for many families. Competition for resources among hospitals can lead to inconsistent treatment availability, ultimately affecting patient outcomes. Regulatory hurdles also present challenges, as the lengthy approval process for new therapies can delay access for clinics and patients alike.

Trends in the China Severe Combined Immunodeficiency (SCID) Market

Buyers and suppliers in the China Severe Combined Immunodeficiency (SCID) Market are adjusting to the following trends.

  • Shift Towards Gene Therapy: Since 2021, there has been a notable shift towards gene therapy as a primary treatment for SCID in China. In 2023, the National Rare Disease Plan included gene therapy, reflecting its growing acceptance among healthcare providers.
  • Increased Focus on Pediatric Care: In 2023, over 200 pediatric hospitals reported SCID cases, highlighting a growing focus on specialised pediatric care for genetic disorders. This trend is leading to improved treatment protocols and better outcomes for affected children.
  • Expansion of Genetic Disorder Centers: The establishment of over 50 genetic disorder centres across China since 2021 has improved access to SCID treatments. These centres play a significant role in diagnosis and management, benefiting numerous patients.
  • Public Awareness Campaigns: In 2023, the Chinese Society of Immunology launched a public awareness campaign about SCID, targeting healthcare providers and families. This initiative aims to improve understanding and treatment access for SCID patients.

Investment Opportunities in the China Severe Combined Immunodeficiency (SCID) Market

Some of the investment opportunities in the China Severe Combined Immunodeficiency (SCID) Market are mentioned below.

  • Growth in Genetic Disorder Centers: With over 50 genetic disorder centres established, there is a strong opportunity to invest in specialised SCID treatment facilities. These centres are essential for improving patient outcomes and can attract funding from healthcare providers.
  • Investment in Pediatric Hospitals: In 2022, the government allocated 500 million CNY for rare disease research, indicating a gap in funding for pediatric hospitals. Investing in these facilities can improve treatment options for SCID patients.
  • Collaborations for Gene Therapy Development: The approval of new gene therapy products in 2023 presents an opportunity for partnerships in research and development. Collaborating with academic institutions can accelerate innovation in SCID treatments.
  • Expansion of Infection Prevention Strategies: With infection prevention strategies emphasised in pediatric care protocols, there is an opportunity to supply advanced infection control products. Pediatric hospitals are key buyers needing these solutions.

Government Initiatives in the China Severe Combined Immunodeficiency (SCID) Market

The National Rare Disease Plan 2021-2025 aims to improve diagnosis and treatment access for SCID patients, overseen by the National Health Commission. This plan includes funding for research and the establishment of specialised treatment centres, enhancing care for affected individuals. The Ministry of Health updated the 'Guidelines for Diagnosis and Treatment of Primary Immunodeficiencies' in 2021, improving standards for SCID care. These measures collectively support better healthcare access and treatment for affected individuals.

The 'Genetic Disorder Management Program' launched by the Ministry of Health in 2022 enhances care for SCID and other genetic disorders. This program provides funding for training healthcare professionals and improving treatment facilities. The Chinese Society of Immunology also initiated a public awareness campaign about SCID in 2023, targeting healthcare providers and families. These initiatives aim to improve understanding and access to SCID treatments, benefiting patients and their families.

Future Insight of the China Severe Combined Immunodeficiency (SCID) Market

The Severe Combined Immunodeficiency market in China is expected to evolve by 2032, driven by advancements in genetic therapies and increased funding for rare disease research. The National Rare Disease Plan aims to improve treatment options, benefiting over 50 genetic disorder centres. The establishment of additional specialised hospitals will facilitate better management of SCID cases. Public awareness initiatives led by health authorities will promote early detection, positively impacting families and healthcare providers.

Market Segmentation Analysis

The analysis below covers each segmentation, its leading category in 2025 and its fastest-growing category through 2032.

By Treatment Type – Gene Therapy Dominated and Is Expected to Record the Fastest Growth

According to Dhaval Chaurasia, Assistant Manager at 6Wresearch, with a 42% revenue share in 2025, Gene Therapy was the largest treatment type category. Gene therapy holds the largest share in the China Severe Combined Immunodeficiency market due to its status as a primary treatment for SCID. With over 200 pediatric hospitals reporting SCID cases, the demand for this advanced therapy continues to grow. Its lead should widen, with a projected CAGR of 5.9% during 2026–2032, the highest in this split. The rapid advancements in gene therapy techniques are propelling its growth, as seen in the National Rare Disease Plan 2021-2025, which includes gene therapy for SCID. This ongoing support ensures that gene therapy will maintain its leading position in the market. Suppliers should focus on expanding gene therapy offerings to meet the increasing demand from healthcare providers.

By Therapy Approach – Targeted DNA Editing Dominated, Donor Stem Cells Expected to Grow Fastest

In 2025, Targeted DNA Editing led the therapy approach split with a 43% share. Targeted DNA editing captures the largest market share as it is a promising therapy for correcting genetic defects associated with SCID. The backing from the National Health Commission for genetic disorder research reinforces its significance in treatment options available in China. The quickest growth will come from Donor Stem Cells, forecast to expand at a CAGR of 7.1% between 2026 and 2032. Donor stem cells are experiencing rapid growth due to their essential role in bone marrow transplants for SCID patients, with over 30 specialized hospitals conducting these procedures. This increasing focus on donor stem cells will likely expand their market share as treatment alternatives develop. Suppliers should focus on advancing donor stem cell therapies to align with the rising demand in SCID treatment protocols.

By Delivery Mode – IV or Injection Dominated, Regular Infusion Expected to Grow Fastest

IV or Injection held a 42% share of the China Severe Combined Immunodeficiency (SCID) Market by delivery mode in 2025. IV or injection is the primary delivery mode for SCID treatments, as it is the most prevalent method for administering therapies in pediatric hospitals. This established practice ensures a steady demand for this delivery method throughout China's healthcare system. Regular Infusion is projected to grow fastest, at a CAGR of 6.7% during 2026–2032. Regular infusion is witnessing the fastest growth, particularly for ongoing therapies like enzyme replacement, which are vital for managing SCID. As the need for consistent treatment escalates, the demand for regular infusion methods is expected to increase significantly. Suppliers must adapt to the growing preference for regular infusion methods to maintain competitiveness in the SCID treatment market.

By End User – Pediatric Hospitals Dominated, Genetic Disorder Centers Expected to Grow Fastest

Pediatric Hospitals took a 49% share of end user in 2025, more than any other category. Pediatric hospitals hold the largest market share as they serve as the primary care facilities for SCID patients, delivering essential treatment and support. Their extensive presence across China ensures a reliable demand for SCID therapies, solidifying their leading position. Genetic Disorder Centers are set to record the highest CAGR in this split, 6.3% over 2026–2032. Genetic disorder centers are rapidly expanding as they concentrate specifically on the diagnosis and treatment of SCID, reflecting a growing awareness and need for specialized care. This trend indicates a shift towards more focused treatment approaches, enhancing their market presence. Providers should strengthen collaborations with genetic disorder centers to improve service delivery and patient outcomes in SCID treatment.

Key Attractiveness of the Report

  • 10 Years of Market Numbers
  • Historical Data Starting from 2022 to 2025
  • Base Year 2025
  • Forecast Data until 2032
  • Key Performance Indicators Impacting the Market
  • Major Upcoming Developments and Projects

Key Highlights of the Report:

  • China Severe Combined Immunodeficiency (SCID) Market Outlook
  • Market Size of China Severe Combined Immunodeficiency (SCID) Market, 2025
  • Forecast of China Severe Combined Immunodeficiency (SCID) Market, 2032
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Revenues & Volume for the Period 2022 - 2032F
  • China Severe Combined Immunodeficiency (SCID) Market Trend Evolution
  • China Severe Combined Immunodeficiency (SCID) Market Drivers and Challenges
  • China Severe Combined Immunodeficiency (SCID) Price Trends
  • China Severe Combined Immunodeficiency (SCID) Porter's Five Forces
  • China Severe Combined Immunodeficiency (SCID) Industry Life Cycle
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Treatment Type for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Gene Therapy for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Bone Marrow Transplant for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Enzyme Replacement for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Antimicrobial Therapy for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Therapy Approach for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Targeted DNA Editing for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Donor Stem Cells for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By PEG-ADA Therapy for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Infection Prevention for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Delivery Mode for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By IV or Injection for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Inpatient Procedure for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Regular Infusion for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Oral/IV for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By End User for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Pediatric Hospitals for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Specialty Clinics for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Genetic Disorder Centers for the Period 2022 - 2032F
  • Historical Data and Forecast of China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume By Immunology Specialists for the Period 2022 - 2032F
  • China Severe Combined Immunodeficiency (SCID) Import Export Trade Statistics
  • Market Opportunity Assessment By Treatment Type
  • Market Opportunity Assessment By Therapy Approach
  • Market Opportunity Assessment By Delivery Mode
  • Market Opportunity Assessment By End User
  • China Severe Combined Immunodeficiency (SCID) Top Companies Market Share
  • China Severe Combined Immunodeficiency (SCID) Competitive Benchmarking By Technical and Operational Parameters
  • China Severe Combined Immunodeficiency (SCID) Company Profiles
  • China Severe Combined Immunodeficiency (SCID) Key Strategic Recommendations

Market Covered

This report examines the market across the segments below.

By Treatment Type

  • Gene Therapy
  • Bone Marrow Transplant
  • Enzyme Replacement
  • Antimicrobial Therapy

By Therapy Approach

  • Targeted DNA Editing
  • Donor Stem Cells
  • PEG-ADA Therapy
  • Infection Prevention

By Delivery Mode

  • IV or Injection
  • Inpatient Procedure
  • Regular Infusion
  • Oral/IV

By End User

  • Pediatric Hospitals
  • Specialty Clinics
  • Genetic Disorder Centers
  • Immunology Specialists

China Severe Combined Immunodeficiency (SCID) Market (2026-2032) FAQs

Donor Stem Cells are the fastest-growing segment at a CAGR of 7.1% during 2026–2032.
The China Severe Combined Immunodeficiency (SCID) Market is projected to reach USD 641.57 million by 2032.
A significant trend is the shift towards gene therapy as a primary treatment for SCID, supported by government initiatives and healthcare provider adoption.
Key demand drivers include support from the National Health Commission, increased awareness among healthcare providers, and the establishment of specialized genetic disorder centers.
The market is expected to grow at a CAGR of approximately 4.9% during 2026–2032, with annual growth peaking at 6.9% in 2030.
6Wresearch actively monitors the China Severe Combined Immunodeficiency (SCID) Market and publishes its comprehensive annual report, highlighting emerging trends, growth drivers, revenue analysis, and forecast outlook. Our insights help businesses to make data-backed strategic decisions with ongoing market dynamics. Our analysts track relevent industries related to the China Severe Combined Immunodeficiency (SCID) Market, allowing our clients with actionable intelligence and reliable forecasts tailored to emerging regional needs.
Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

1 Executive Summary

2 Introduction

2.1 Key Highlights of the Report

2.2 Report Description

2.3 Market Scope & Segmentation

2.4 Research Methodology

2.5 Assumptions

3 China Severe Combined Immunodeficiency (SCID) Market Overview

3.1 China Country Macro Economic Indicators

3.2 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, 2022 & 2032F

3.3 China Severe Combined Immunodeficiency (SCID) Market - Industry Life Cycle

3.4 China Severe Combined Immunodeficiency (SCID) Market - Porter's Five Forces

3.5 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume Share, By Treatment Type, 2022 & 2032F

3.6 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume Share, By Therapy Approach, 2022 & 2032F

3.7 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume Share, By Delivery Mode, 2022 & 2032F

3.8 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume Share, By End User, 2022 & 2032F

4 China Severe Combined Immunodeficiency (SCID) Market Dynamics

4.1 Impact Analysis

4.2 Market Drivers

4.3 Market Restraints

5 China Severe Combined Immunodeficiency (SCID) Market Trends

6 China Severe Combined Immunodeficiency (SCID) Market, By Types

6.1 China Severe Combined Immunodeficiency (SCID) Market, By Treatment Type

6.1.1 Overview and Analysis

6.1.2 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Treatment Type, 2022 - 2032F

6.1.3 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Gene Therapy, 2022 - 2032F

6.1.4 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Bone Marrow Transplant, 2022 - 2032F

6.1.5 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Enzyme Replacement, 2022 - 2032F

6.1.6 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Antimicrobial Therapy, 2022 - 2032F

6.2 China Severe Combined Immunodeficiency (SCID) Market, By Therapy Approach

6.2.1 Overview and Analysis

6.2.2 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Targeted DNA Editing, 2022 - 2032F

6.2.3 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Donor Stem Cells, 2022 - 2032F

6.2.4 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By PEG-ADA Therapy, 2022 - 2032F

6.2.5 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Infection Prevention, 2022 - 2032F

6.3 China Severe Combined Immunodeficiency (SCID) Market, By Delivery Mode

6.3.1 Overview and Analysis

6.3.2 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By IV or Injection, 2022 - 2032F

6.3.3 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Inpatient Procedure, 2022 - 2032F

6.3.4 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Regular Infusion, 2022 - 2032F

6.3.5 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Oral/IV, 2022 - 2032F

6.4 China Severe Combined Immunodeficiency (SCID) Market, By End User

6.4.1 Overview and Analysis

6.4.2 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Pediatric Hospitals, 2022 - 2032F

6.4.3 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Specialty Clinics, 2022 - 2032F

6.4.4 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Genetic Disorder Centers, 2022 - 2032F

6.4.5 China Severe Combined Immunodeficiency (SCID) Market Revenues & Volume, By Immunology Specialists, 2022 - 2032F

7 China Severe Combined Immunodeficiency (SCID) Market Import-Export Trade Statistics

7.1 China Severe Combined Immunodeficiency (SCID) Market Export to Major Countries

7.2 China Severe Combined Immunodeficiency (SCID) Market Imports from Major Countries

8 China Severe Combined Immunodeficiency (SCID) Market Key Performance Indicators

9 China Severe Combined Immunodeficiency (SCID) Market - Opportunity Assessment

9.1 China Severe Combined Immunodeficiency (SCID) Market Opportunity Assessment, By Treatment Type, 2022 & 2032F

9.2 China Severe Combined Immunodeficiency (SCID) Market Opportunity Assessment, By Therapy Approach, 2022 & 2032F

9.3 China Severe Combined Immunodeficiency (SCID) Market Opportunity Assessment, By Delivery Mode, 2022 & 2032F

9.4 China Severe Combined Immunodeficiency (SCID) Market Opportunity Assessment, By End User, 2022 & 2032F

10 China Severe Combined Immunodeficiency (SCID) Market - Competitive Landscape

10.1 China Severe Combined Immunodeficiency (SCID) Market Revenue Share, By Companies, 2025

10.2 China Severe Combined Immunodeficiency (SCID) Market Competitive Benchmarking, By Operating and Technical Parameters

11 Company Profiles

12 Recommendations

13 Disclaimer

Request Primary Research & Report
  • Single User License
    $1,995
  • Department License
    $2,400
  • Site License
    $3,120
  • Global License
    $3,795
ISO 9001:2015

ISO 9001:2015 CERTIFIED

Quality Management System for market research & advisory services

Cert. No. 3050261008135Q

6Wresearch Support

Any Query

Call: +91-11-4302-4305
Email us: sales@6wresearch.com
Any Query? Click Here
6WExportGTM
GLOBAL TRADE INTELLIGENCE
◎

Unlock Your Export Potential

Discover product and sector-level opportunities to identify untapped export potential.

Product / Sector Level Analysis

Find Your Next Trading Partner

Identify promising international markets and discover the right countries to expand your business.

Top Trading Partners

Know Where to Invest

Uncover high-potential markets and make informed decisions about your next investment opportunity.

Where to Invest

Stay Ahead of Competition

Understand the competitive landscape, identify key players and discover gaps in global markets.

Market Competition Analysis

Leadership Perspectives from Industry Events

6Wresearch in the News

Thought Leadership and Analyst Meet

Our Clients

Airtel
Canon
Contec
HoneyWell
Kriloskar
Pwc Logo
Samsung
Tata Teleservices

Industry Events and Analyst Meet

Whitepaper

Read All